Thursday, November 10, 2016 9:19:56 AM
Marketwired MarketwiredNovember 10, 2016Comment
NEW YORK, NY--(Marketwired - Nov 10, 2016) - iBio, Inc. ( NYSE MKT : IBIO ), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced completion of expanded product development capacity of its subsidiary, iBio CMO LLC, for the production of pharmaceutical proteins in hydroponically-grown green plants. This expansion enables iBio CMO's use of iBio proprietary technologies to conduct concurrent product development work for multiple clients in multiple product classes with time-saving transitions from laboratory-level feasibility and testing through cGMP production of active pharmaceutical ingredients for toxicology studies and phase 1 human clinical trials.
"An important consideration for many of our clients and prospective clients is our ability to save them time during critical stages of their proprietary product development programs," said Dr. Barry Holtz, iBio's senior vice president of product development and manufacturing. "We can provide definitive technical answers faster than conventional mammalian cell-based systems and then move directly into larger scale production. This avoids engineering and reengineering mammalian cell lines and dealing with the scale-up issues associated with traditional CHO cell production."
iBio is currently engaged in development of several vaccine and therapeutic candidates for third party clients and is significantly expanding its commitment to the monoclonal antibody product category. The pilot plant expansion enables the company to remain fully committed to its own proprietary anti-fibrosis therapeutics program while taking on promising programs with quality clients.
Recent IBIO News
- iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases • GlobeNewswire Inc. • 03/27/2024 11:00:00 AM
- iBio Announces $15.0 Million Private Placement • GlobeNewswire Inc. • 03/26/2024 11:35:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:59:30 PM
- iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka • GlobeNewswire Inc. • 02/26/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:55:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:36:09 PM
- iBio Announces Participation in 23rd Annual PepTalk Conference • GlobeNewswire Inc. • 01/16/2024 01:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/10/2024 06:24:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:30:59 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/04/2024 01:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 12:44:38 PM
- iBio Amends and Extends Maturity of Credit Agreement • GlobeNewswire Inc. • 12/26/2023 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 09:17:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 02:13:08 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/06/2023 01:59:51 PM
- iBio, Inc. Announces Pricing of $4.5 Million Public Offering • GlobeNewswire Inc. • 12/05/2023 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/05/2023 05:15:18 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/30/2023 01:55:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 01:36:43 PM
- iBio Announces Reverse Stock Split • GlobeNewswire Inc. • 11/27/2023 10:20:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:01:14 PM
- iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific • GlobeNewswire Inc. • 11/01/2023 12:24:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/27/2023 08:29:45 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/26/2023 12:20:58 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM